ArticleMolecular and cellular biology1995
Ras p21Val inhibits myogenesis without altering the DNA binding or transcriptional activities of the myogenic basic helix-loop-helix factors.
Article in Molecular and cellular biology, 1995. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 69 citations in OpenAlex.
- A role for Regulator of G protein Signaling-12 (RGS12) in the balance between myoblast proliferation and differentiation.PloS one · 2019Article
- Myopathy caused by HRAS germline mutations: implications for disturbed myogenic differentiation in the presence of constitutive HRas activation.Journal of medical genetics · 2007Article
- Thioredoxin reductase regulates the induction of haem oxygenase-1 expression in aortic endothelial cells.The Biochemical journal · 2006Article
- Cell cycle in mouse development.Oncogene · 2005Review
- Inhibition of Mist1 homodimer formation induces pancreatic acinar-to-ductal metaplasia.Molecular and cellular biology · 2004Article
- Transforming growth factor-beta1 induces the differentiation of myogenic cells into fibrotic cells in injured skeletal muscle: a key event in muscle fibrogenesis.The American journal of pathology · 2004Article
- Article
- Rb and N-ras function together to control differentiation in the mouse.Molecular and cellular biology · 2003Article
- Identification of novel MyoD gene targets in proliferating myogenic stem cells.Molecular and cellular biology · 2002Article
- TGF-beta inhibits muscle differentiation through functional repression of myogenic transcription factors by Smad3.Genes & development · 2001Article
- Article
- Multiple ras downstream pathways mediate functional repression of the homeobox gene product TTF-1.Molecular and cellular biology · 2000Article
- The retinoblastoma protein is linked to the activation of Ras.Molecular and cellular biology · 1999Article
- Distinct effects of Rac1 on differentiation of primary avian myoblasts.Molecular biology of the cell · 1999Article
- Article
- Article
- CDO, a robo-related cell surface protein that mediates myogenic differentiation.The Journal of cell biology · 1998Article
- Notch inhibition of E47 supports the existence of a novel signaling pathway.Molecular and cellular biology · 1998Article
- The basic helix-loop-helix transcription factor Mist1 functions as a transcriptional repressor of myoD.The EMBO journal · 1998Article
- The Rho family G proteins play a critical role in muscle differentiation.Molecular and cellular biology · 1998Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MRF4, MyoD, myogenin, and Myf-5 are muscle-specific basic helix-loop-helix transcription factors that share the ability to activate the expression of skeletal muscle genes such as those encoding alpha-actin, myosin heavy chain, and the acetylcholine receptor subunits. The muscle regulatory factors (MRFs) also exhibit the unique capacity to initiate the myogenic program when ectopically expressed in a variety of nonmuscle cell types, most notably C3H10T1/2 fibroblasts (10T1/2 cells). The commitment of myoblasts to terminal differentiation, although positively regulated by the MRFs, also is controlled negatively by a variety of agents, including several growth factors and oncoproteins such as fibroblast growth factor (FGF-2), transforming growth factor beta 1 (TGF-beta 1), and Ras p21Val. The molecular mechanisms by which these varied agents alter myogenic terminal differentiation events remain unclear. In an effort to establish whether Ras p21Val represses MRF activity by directly targeting the MRF proteins, we examined the DNA binding and transcription activation potentials of MRF4 and MyoD when expressed in 10T1/2 cells or in 10T1/2 cells expressing Ras p21Val. Our results demonstrate that Ras p21Val inhibits terminal differentiation events by targeting the basic domain of the MRFs, and yet the mechanism underlying this inhibition does not involve altering the DNA binding or the inherent transcriptional activity of these regulatory factors. In contrast, FGF-2 and TGF-beta 1 block terminal differentiation by repressing the transcriptional activity of the MRFs. We conclude that the Ras p21Val block in differentiation operates via an intracellular signaling pathway that is distinct from the FGF-2 and TGF-beta 1 pathways.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.